BioNTech Common Stock Total Equity vs Net Receivables Analysis
BNTX Stock | USD 94.10 2.85 2.94% |
BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Common Stock Total Equity and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
Common Stock Total Equity vs Net Receivables
Common Stock Total Equity vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Common Stock Total Equity account and Net Receivables. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between BioNTech's Common Stock Total Equity and Net Receivables is 0.52. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Net Receivables in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Common Stock Total Equity and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of BioNTech SE are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Common Stock Total Equity i.e., BioNTech's Common Stock Total Equity and Net Receivables go up and down completely randomly.
Correlation Coefficient | 0.52 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Net Receivables
Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. At this time, BioNTech's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.21 in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.
BioNTech fundamental ratios Correlations
Click cells to compare fundamentals
BioNTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioNTech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 797.6M | 2.3B | 15.8B | 23.3B | 23.0B | 24.2B | |
Short Long Term Debt Total | 68.9M | 240.2M | 301.5M | 212.2M | 219.1M | 161.3M | |
Other Current Liab | 16.4M | 103.1M | 3.0B | 2.6B | 1.3B | 979.8M | |
Total Current Liabilities | 138.1M | 606.0M | 3.5B | 3.0B | 2.1B | 1.3B | |
Total Stockholder Equity | 493.5M | 1.4B | 11.9B | 20.1B | 20.2B | 21.3B | |
Other Liab | 205.6M | 97.1M | 109.7M | 283.9M | 326.5M | 166.9M | |
Net Tangible Assets | 179.6M | 406.5M | 1.2B | 11.7B | 13.5B | 14.1B | |
Property Plant And Equipment Net | 148.1M | 326.0M | 520.4M | 821.1M | 971.6M | 1.0B | |
Current Deferred Revenue | 93.6M | 391.5M | 189.1M | 77.1M | 353.3M | 371.0M | |
Net Debt | (450.2M) | (970.0M) | (1.4B) | (13.7B) | (11.4B) | (10.9B) | |
Retained Earnings | (424.8M) | (409.6M) | 9.9B | 18.8B | 19.8B | 20.8B | |
Accounts Payable | 20.5M | 102.3M | 160M | 204.1M | 354M | 371.7M | |
Cash | 519.1M | 1.2B | 1.7B | 13.9B | 11.7B | 12.2B | |
Non Current Assets Total | 237.5M | 651.7M | 758.5M | 1.4B | 3.5B | 3.7B | |
Non Currrent Assets Other | 2K | 1.0M | 800K | 6.5M | 83.4M | 87.6M | |
Other Assets | 2.4M | 168.2M | 22.2M | 249.2M | 286.6M | 300.9M | |
Long Term Debt | 68.9M | 231.0M | 171.6M | 176.2M | 191M | 116.1M | |
Cash And Short Term Investments | 520.8M | 1.3B | 2.1B | 14.1B | 16.5B | 17.4B | |
Net Receivables | 20.2M | 166.4M | 12.4B | 7.1B | 2.3B | 3.0B | |
Good Will | 3.0M | 53.7M | 57.8M | 61.2M | 362.5M | 380.6M | |
Common Stock Total Equity | 166.8M | 193.3M | 232.3M | 246.3M | 283.3M | 185.2M | |
Common Stock Shares Outstanding | 211.5M | 248.5M | 259.7M | 249.8M | 242.7M | 229.1M | |
Short Term Investments | 1.7M | 137.2M | 381.6M | 189.4M | 4.9B | 5.1B | |
Liabilities And Stockholders Equity | 797.6M | 2.3B | 15.8B | 23.3B | 23.0B | 24.2B | |
Non Current Liabilities Total | 166.0M | 340.8M | 455.5M | 272.9M | 689.9M | 378.2M | |
Inventory | 11.7M | 64.1M | 502.5M | 439.6M | 357.7M | 190.9M | |
Other Current Assets | 1.2M | 61.0M | 64.9M | 271.9M | 280.9M | 294.9M | |
Other Stockholder Equity | (5.5M) | 1.5B | (3.8M) | (5.3M) | 1.2B | 1.3B | |
Total Liab | 304.2M | 946.8M | 3.9B | 3.2B | 2.8B | 1.7B | |
Property Plant And Equipment Gross | 148.1M | 326.0M | 594.6M | 821.1M | 1.2B | 1.2B | |
Total Current Assets | 560.2M | 1.7B | 15.1B | 21.9B | 19.5B | 20.5B | |
Accumulated Other Comprehensive Income | 691.5M | 25.5M | 1.8B | 979.3M | (984.6M) | (935.4M) | |
Short Term Debt | 7.6M | 9.1M | 129.9M | 36M | 28.1M | 32.9M | |
Intangible Assets | 86.5M | 109.8M | 144.6M | 158.5M | 804.1M | 844.3M | |
Common Stock | 232.3M | 246.3M | 246.3M | 248.6M | 285.9M | 218.0M | |
Property Plant Equipment | 116.0M | 148.1M | 326.0M | 520.4M | 598.5M | 628.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 0.5 | Revenue Per Share 11.369 | Quarterly Revenue Growth (0.85) | Return On Assets (0.01) |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.